Receptor News and Research

RSS

Using HIV drugs to treat AMD: an interview with Dr Mark Young

NRTIs are compounds which were originally developed in the 1960s as anti-cancer agents. They are similar in structure to the bases which make up DNA, and it was hoped that they would interfere with DNA replication in fast-growing cancer cells, slowing down or stopping tumour growth.

7 Jan 2015

U-M researchers reveal key gene that may provide potential target for cancer treatment

One of the mysteries in cancer biology is how one protein, TGF-beta, can both stop cancer from forming and encourage its aggressive growth.

6 Jan 2015

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors.

6 Jan 2015

Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Clementia Pharmaceuticals, Inc. today announced that it has secured an additional $10 million from current investors to support development of the company's lead compound palovarotene for the treatment of fibrodysplasia ossificans progressive (FOP).

5 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it completed the design of the Rheumatoid Arthritis (RA) Phase III study of its lead drug candidate CF101.

31 Dec 2014

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology.

30 Dec 2014

Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program.

29 Dec 2014

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management.

25 Dec 2014

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

Radiation/chemotherapy increases risk of leukemia in early-stage breast cancer patients

The risk of developing leukemia after radiation therapy or chemotherapy for early stage breast cancer remains very small, but it is twice as high as previously reported, according to results of a new study led by researchers at the Johns Hopkins Kimmel Cancer Center.

23 Dec 2014

UCLA researchers uncover potential to restore lost memories in patients with early Alzheimer's

New UCLA research indicates that lost memories can be restored. The findings offer some hope for patients in the early stages of Alzheimer's disease.

23 Dec 2014

Eating habits and brain chemistry: an interview with Dr Kevin Hall

Several times every day, we choose when, where, what, with whom, and how much to eat. Many of these eating decisions have become automatic and don’t require cognitive effort.

22 Dec 2014

Mexican study shows mobility can be restored in patients with Parkinson's disease

Mexican scientists demonstrated experimentally, with adult rats, that mobility can be restored in patients with Parkinson's disease, the major degenerative disease of the motor system worldwide.

22 Dec 2014

Chromosome X microduplications implicated in infancy-onset gigantism

Researchers report that heritable microduplications on chromosome Xq26.3 may underlie a “striking” form of gigantism with onset in late infancy, and reveal a candidate culprit gene.

22 Dec 2014

Novo Nordisk gets positive CHMP opinion for expanded use of Tresiba in children with diabetes

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged one to 17 years with diabetes.

From Novo Nordisk 22 Dec 2014

Study: Inactivating polymorphism may influence progression of ovarian and luminal breast cancer

A common polymorphism - a variation in a person's DNA sequence that is found with regularity in the general population - can lead to a chain of events that dictates how a tumor will progress in certain types of cancer, including a form of breast cancer as well as ovarian cancer, according to new research from The Wistar Institute that was published online by the journal Cancer Cell.

19 Dec 2014

Long-term axitinib in RCC effective with ‘controllable’ toxicities

Axitinib treatment is effective in the long-term in Japanese patients with metastatic renal cell carcinoma and has manageable toxicity, a phase II study suggests.

19 Dec 2014

Gene variations predispose mestizo Mexican population to develop severe form of COPD

A study by Ramcés Falfán-Valencia, researcher at the National Institute of Respiratory Diseases, found that the mestizo Mexican population has a number of variations in certain genes that predispose them to develop the most severe form of chronic obstructive pulmonary disease (COPD).

19 Dec 2014

UTSA, UTHSCSA researchers to jointly develop next-generation breast cancer treatment drugs

Stanton McHardy, associate professor of chemistry and director of the Center for Innovative Drug Discovery in The University of Texas at San Antonio College of Sciences, is partnering on a $1.9 million award to develop next-generation breast cancer treatment drugs.

19 Dec 2014

Receptor News and Research

Using HIV drugs to treat AMD: an interview with Dr Mark Young

U-M researchers reveal key gene that may provide potential target for cancer treatment

FDA receives Actavis' NDA resubmission for cariprazine

Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Early use of heart failure drugs slows cardiac damage in boys, young men with DMD

Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction

FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Radiation/chemotherapy increases risk of leukemia in early-stage breast cancer patients

UCLA researchers uncover potential to restore lost memories in patients with early Alzheimer's

Eating habits and brain chemistry: an interview with Dr Kevin Hall

Mexican study shows mobility can be restored in patients with Parkinson's disease

Chromosome X microduplications implicated in infancy-onset gigantism

Novo Nordisk gets positive CHMP opinion for expanded use of Tresiba in children with diabetes

Study: Inactivating polymorphism may influence progression of ovarian and luminal breast cancer

Long-term axitinib in RCC effective with ‘controllable’ toxicities

Gene variations predispose mestizo Mexican population to develop severe form of COPD

UTSA, UTHSCSA researchers to jointly develop next-generation breast cancer treatment drugs

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News